Aims: To examine possible effects of polymorphism in the SLCO1B1 gene, encoding the hepatic uptake transporter organic anion transporting polypeptide (OATP) 1B1, on the pharmacokinetics of rosiglitazone and pioglitazone in a prospective genotype panel study.
Methods: Sixteen healthy volunteers with the homozygous SLCO1B1 c.521TT genotype (controls), 12 with the heterozygous c.521TC genotype and four with the homozygous c.521CC genotype ingested a single 4-mg dose of rosiglitazone and a single 15-mg dose of pioglitazone in a cross-over study with a wash-out period of at least 1 week.
Results: SLCO1B1 polymorphism had no statistically significant effect on any of the pharmacokinetic variables of rosiglitazone, pioglitazone or their metabolites. The mean +/- SD area under the plasma rosiglitazone concentration-time curve from time 0 to infinity (AUC(0-infinity)) was 2024 +/- 561 ng ml(-1) h in the c.521TT subjects, 1763 +/- 288 ng ml(-1) h in the c.521TC subjects (geometric mean ratio c.521TC/c.521TT 0.89; 95% confidence interval 0.72, 1.11) and 1729 +/- 346 ng ml(-1) h in the c.521CC subjects (c.521CC/c.521TT 0.87; 0.63, 1.20). The AUC(0-infinity) of pioglitazone averaged 6244 +/- 1909 ng ml(-1) h in the c.521TT subjects, 5123 +/- 1165 ng ml(-1) h in the c.521TC subjects (c.521TC/c.521TT 0.83; 0.65, 1.06) and 4851 +/- 1123 ng ml(-1) h in the c.521CC subjects (c.521CC/c.521TT 0.79; 0.55, 1.14). There was a significant correlation between the AUC(0-infinity) of rosiglitazone and pioglitazone (r = 0.717, P < 0.001).
Conclusions: The SLCO1B1 c.521T-->C SNP does not affect the pharmacokinetics of rosiglitazone or pioglitazone, indicating that OATP1B1 plays no significant role in the disposition of these drugs.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2291278 | PMC |
| http://dx.doi.org/10.1111/j.1365-2125.2007.02986.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Masking in Active Comparator Designs in Pharmacovigilance: A Retrospective Bias Analysis on the Spontaneous Reporting of Thiazolidinediones and Cardiovascular Events.
Pharmacoepidemiol Drug Saf
January 2025
School of Epidemiology and Public Health, University of Ottawa, Ottawa, Ontario, Canada.
Introduction: Masking is a reporting bias where drug safety signals are muffled by elevated reporting of other medications in spontaneous reporting databases. While the impact of masking is often limited, its effect when using restricted designs, such as active comparators, can be consequential.
Methods: We used data from the US Food and Drugs Administration Adverse Event Reporting System (1999Q3-2013Q3) to study masking in a real-world example.
Integrative analysis of toxicometabolomics and toxicoproteomics data: new molecular insights into thiazolidinedione-induced cardiotoxicity.
Metabolomics
December 2024
Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, 161 Cathedral Street, Glasgow, G4 0RE, UK.
Article Synopsis
- Thiazolidinediones (TZDs), like pioglitazone and rosiglitazone, are effective for treating type II diabetes but raise concerns about their role in heart failure risk, creating safety uncertainties that limit their use.
- This study employed a multi-omics approach to explore the mechanisms behind TZD-induced heart toxicity, revealing significant alterations in biochemical pathways related to energy metabolism and a shift towards anaerobic glycolysis in heart cells.
- Findings highlighted disruptions in the glutathione system and identified specific amino acid signatures linked to heart failure, suggesting these could be useful for early detection of TZD-related cardiotoxicity and potential therapeutic targets in the future.
Hypoglycemic Agents Increase Regulatory Factor X1 to Inhibit Cancer Cell Behaviour in Human Glioblastoma Cells.
J Cell Mol Med
December 2024
Department of Anesthesiology, University of Virginia, Charlottesville, Virginia, USA.
Article Synopsis
- Glioblastoma multiforme is a highly aggressive brain tumor, and research has found that the transcription factor RFX1 can inhibit the growth and spread of these tumor cells.
- The study identified existing medications that could boost RFX1 levels in glioblastoma cells, using bioinformatics and laboratory testing, confirming that drugs like pioglitazone and rosiglitazone effectively promote RFX1.
- These hypoglycemic medications were shown to decrease cancer cell proliferation and invasion, primarily by reducing metalloproteinase 2 (MMP2) activity, making RFX1 a potential therapeutic target for glioblastoma treatment.
Thiazolidinedione derivatives in cancer therapy: exploring novel mechanisms, therapeutic potentials, and future horizons in oncology.
Naunyn Schmiedebergs Arch Pharmacol
December 2024
Department of Pharmacy, School of Health Sciences, Central University of South Bihar, Gaya, 824236, India.
Thiazolidinedione derivatives have shown significant potential as targeted cancer therapies by leveraging their various mechanisms of action. These include suppressing cell proliferation, triggering apoptosis, and influencing signaling pathways associated with tumor development. Their multifaceted effects make them promising candidates for advancing cancer treatment strategies.
View Article and Find Full Text PDFBridging gap in treatment of polycystic ovarian syndrome through drug repurposing: what we achieved and where we are?
Naunyn Schmiedebergs Arch Pharmacol
November 2024
Department of Pharmaceutical Sciences and Technology, Institute of Chemical Technology, Matunga, Mumbai, Maharashtra, 400019, India.
Polycystic ovarian syndrome (PCOS) is one of the chief causes of infertility in women of reproductive age. Several drugs belonging to the oral contraceptive class have been approved for the treatment of PCOS. Nonetheless, the capability to target only a few symptoms of PCOS and fatal side effects are key hurdles to their use.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!